{"entity":{"id":"drd5","kind":"target","name":"DRD5","aka":["dopamine receptor D5","Dopamine receptor D5","DRD1B","DRD1L2"],"tldr":"DRD5 (Dopamine receptor D5) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","summary":"G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Dopamine receptors can be classified in two categories: (1) DRD5 (together with DRD1) is a D1-type receptor and is coupled to G(s) G proteins, mediating activation of adenylate cyclase activity, while D2-type receptors (DRD2, DRD3 and DRD4) are coupled to G(i)/G(o) G proteins and promote inhibition of adenylate cyclase activity.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Dordaviprone.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3026","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3026"},{"label":"UniProt P21918","url":"https://www.uniprot.org/uniprotkb/P21918/entry"},{"label":"NCBI Gene 1816","url":"https://www.ncbi.nlm.nih.gov/gene/1816"},{"label":"Ensembl ENSG00000169676","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000169676"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"DRD5","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:3026","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3026","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P21918","url":"https://www.uniprot.org/uniprotkb/P21918/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene DRD5","url":"https://civicdb.org/features/1536","note":"1 evidence items, 0 assertions, 1 variants; diseases: Glioblastoma (GraphQL API, CC0)"}],"hgnc":"HGNC:3026","ensembl":"ENSG00000169676","uniprot":"P21918","entrez":"1816","biology":"G protein-coupled receptor for dopamine, a catecholamine neurotransmitter hormone that functions as the brain's 'reward chemical', driving motivation, reinforcement learning and pleasure. Dopamine binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. Dopamine receptors can be classified in two categories: (1) DRD5 (together with DRD1) is a D1-type receptor and is coupled to G(s) G proteins, mediating activation of adenylate cyclase activity, while D2-type receptors (DRD2, DRD3 and DRD4) are coupled to G(i)/G(o) G proteins and promote inhibition of adenylate cyclase activity. D1- and D2-type dopamine receptors have antagonistic effects, particularly in the brain's striatum, where they govern voluntary movement and reward: D1-type receptors generally stimulate neural activity and promotes action, while D2-type receptors tend to inhibit neural activity and suppress movement. DRD5 acts as a key regulator of blood pressure: negatively regulates the renin-angiotensin system (RAS), thereby reducing renal sodium absorption by the kidney. Location: Cell membrane (UniProt). Locus 4p16.1 (HGNC).","whereFound":["Glioma & glioblastoma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/drd5/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}